On November 14, 2026 CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, reported that satricabtagene autoleucel ("satri-cel", product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the Commercial Health Insurance Innovative Drug List (2026) (the "CHIIDL") issued by the National Healthcare Security Administration ("NHSA") and the Ministry of Human Resources and Social Security ("MOHRSS"), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. The new list was published today by the NHSA at a press conference held in Suzhou, and will officially take effect on January 1, 2027.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CHIIDL primarily covers innovative drugs that go beyond the "basic coverage" mandate of the national basic medical insurance scheme and therefore cannot yet be included in the basic reimbursement list, but which are highly innovative, of significant clinical value, deliver substantial patient benefit, and are well suited to insurance coverage. It provides a payment basis for China’s multi-tiered healthcare security system, including commercial health insurance and mutual medical aid. Satri-cel is the first CAR T-cell therapy product for solid tumors to be included in the CHIIDL since the list was established, marking an extension of the multi-tiered healthcare security system’s support for CAR T-cell therapy from hematologic malignancies into solid tumors, which affect a considerably larger patient population.
Taking this inclusion as an opportunity, CARsgen will, on the premise of doing its utmost to ensure product quality and a stable supply, actively support the design and implementation of commercial insurance products and accelerate market access at healthcare institutions and standardized clinical use, so as to bring this first-in-class cell therapy product to more patients as soon as possible.
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, "Satri-cel was approved in China this June and has been included in the national CHIIDL within the same year. This is recognition at the national level of the clinical value and the innovation of the world’s first CAR T-cell therapy for solid tumors. The CHIIDL establishes an institutionalized payment channel for high-value innovative therapies outside basic medical insurance, and brings us one step closer to truly bringing this first-in-class achievement to patients. The Company will continue to build the payment and service ecosystem together with insurers and healthcare institutions, so as to make diversified payment a workable and ever-broadening pathway."
About Satri-cel
Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.
The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).
(Press release, Carsgen Therapeutics, NOV 14, 2026, View Source [SID1234674784])